Trastuzumab brengitecan
Antibody–drug conjugate
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-12.
Also in development:HER2-Positive Breast Cancer · Phase 3Ovarian Cancer · Phase 3Colorectal Cancer · Phase 3Biliary Tract Cancer · Phase 3Urothelial Carcinoma · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07178795 NCT07178795 · Non-Small Cell Lung Cancer Registry: NCT07178795 | 3 | Progression-free survival (PFS) (Up to approximately 24 months) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other HER2 drugs
margetuximab, Trastuzumab Deruxtecan, Tucatinib, Zanidatamab, Disitamab Vedotin and 11 more. Compare all 17 HER2 drugs
This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.
This drug's own stage for Biliary Tract Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Trastuzumab Brengitecan: this drug | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | Weak signal | NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | |
| Futibatinib (Lytgobi) | Phase 3 | Small molecule | FGFR (FGFR1/2/3/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Ivonescimab | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Tovecimig | Phase 2/3 | Multispecific antibody | DLL4 x VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Phase 2 | Monoclonal antibody | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| RAD202 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Trastuzumab brengitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.